

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
Shanler, et al. : Confirmation No.: 4999
Serial No. 10/763,807 : Group Art Unit: 1617
Filed: January 22, 2004 : Examiner: Abigail Manda Cotton

For: METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS
FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING
 α_1 . ADRENOCEPTOR AGONISTS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink, appearing to read 'Raymond A. Miller', with a long horizontal flourish extending to the right.

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
One Mellon Bank Center
50th Floor
500 Grant Street
Pittsburgh, PA 15219
Telephone: (412) 454-5813
Facsimile: (412) 281-0717
Date: July 20, 2007

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known				
				Application Number	10/763,807			
				Filing Date	January 22, 2004			
				First Named Inventor	Shanler			
				Group Art Unit	1617			
				Examiner Name	Abigail Manda Cotton			
Sheet	1	of	2	Attorney Docket Number	132957.00101			
U.S. PATENT DOCUMENTS								
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		Number	Kind Code (if known)					
	A1	2007/0048234	A1	Waugh et al.	03-01-2007			
	A2	2005/0256204	A1	Bitter, Sr.	11-17-2005			
	A3	2005/0222101	A1	Huttrer	10-06-2005			
	A4	2004/0220259	A1	Yu et al.	11-04-2004			
	A5	2006/0264515		DeJovin et al.	11-23-2006			
	A6	2006/0171974		DeJovin et al.	08-03-2006			
	A7	2005/0276830		DeJovin et al.	12-15-2005			
	A8	2004/0242588		DeJovin et al.	12-02-2004			
	A9	4,853,216		Koslo et al.	08-01-1989			
	A10	2007/0082070	A1	Stokey et al.	04-12-2007			
FOREIGN PATENT DOCUMENTS								
Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)								
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.						
	C1	CRAWFORD et al., Rosacea: I. Etiology, pathogenesis, and subtype classification, Sept. 2004, J. Am. Acad. Dermatol. 51(3):327-341						
	C2	PELLE et al., Rosacea: II. Therapy, Oct. 2004, Am. Acad. Dermatol. 51(4):499-512						
	C3	WILKIN et al., Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea, 2002, 46(4):584-587						
	C4	PLEWIG et al., Acne and Rosacea, Acne and Rosacea, 2 nd Rev. Ed., Springer-Verlag Berlin, pp.433-475						
	C5	WILKIN, Why is flushing limited to a mostly facial curaneous distribution?, Aug. 1988, J. Am. Acad. Dermatol. 2(1):309-313						
	C6	WILKIN, Oral Thermal-Induced Flushing in Erythematotelangiectatic Rosacea, 1981, J. Invest. Dermatol. 76:15-18						
	C7	PARODI et al., Flusjng in Rosacea: An Experimental Approach, 1980, Archives of Dermatol. Res., Springer-Verlag, 269:269-273						
	C8	AHLQUIST, A Study of the Adrenotropic Receptors, June 1948, Adrenotropic Receptors 153:586-600						
	C9	KIRSTEIN et al., Autonomic Nervous System Pharmacogenomics: A Progress Report, 2004, Pharmacol. Rev. 56(1):31-52						
	C10	PIASCIK et al., α_1 -Adrenergic Receptors: New Insights and Directions, 2001, J. Pharmacol. and Exper. Therap. 298(2):403-410						
	C11	CALZADA et al., Alpha-Adrenoceptor Subtypes, 2001, Pharmacol. Res. 44(3):195-207						
Examiner Signature					Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/763,807
				Filing Date	January 22, 2004
				First Named Inventor	Shanler
				Group Art Unit	1617
				Examiner Name	Abigail Manda Cotton
Sheet	2	of	2	Attorney Docket Number	132957.00101
	C12	GUIMARAES et al., Vascular Adrenoceptors: An Update, 2001, Am. Soc. Pharmacol. and Exper. Therapeutics, Pharmacol. Rev. 53(2):319-356			
	C13	HIEBLE, Subclassification and Nomenclature of α - and β -Adrenoceptors, 2007, Curr. Topics in Medicinal Chem. 7:129-134			
	C14	JARAJAPU et al., Functional Characterization of α_1 -Adrenoceptor Subtypes in Human Subcutaneous Resistance Arteries, 2001, J. Pharmacol. and Exp. Therapeutics 299(2):729-734			
	C15	LEECH et al., Different α -adrenoceptor subtypes mediate constriction of arterioles and venules, 1996, Am. Phys. Soc., pps. H710-H722			
	C16	CHALOTHORN et al., Differences in the Cellular Localization and Agonist-Mediated Internalization Properties of the α_1 -Adrenoceptor Subtypes, 2002, Molec. Pharmacol. 61(5):1008-1016			
	C17	BISHOP, Recent Advances in the Discovery of α_1 -Adrenoceptor Agonists, 2007, Curr. Topics Med. Chem. 7:135-145			
	C18	CRASSOUS et al., Interest of α_2 -Adrenergic Agonists and Antagonists in Clinical Practice: Background, Facts and Perspectives, 2007, Curr. Topics med. Chem. 7:187-194			
	C19	GENTILI et al., Agonists and Antagonists Targeting the Different α_2 -Adrenoceptor Subtypes, 2007, Curr. Topics Med. Chem. 7:163-186			
	C20	SPEAKE et al., 2-(Anilinomethyl)imidazolines as α_1 Adrenergic Receptor Agonists: α_{1A} Subtype Selective 2' Heteroaryl Compounds, 2003, Bioorganic & Med. Chem. Letters 13:1183-1186			
	C21	IGINI et al., Structure-Activity Relationship at α -Adrenergic Receptors Within a Series of Imidazoline Analogues of Cirazoline, 2000, Bioorganic & Med. Chem. 8:883-888			
	C22	CROSS et al., Transdermal and Penetration of Vasoconstrictors—Present Understanding and Assessment of the Human Epidermal Flux and Retention of Free Bases and Ion-Pairs, Feb. 2003, Pharma. Res. 20(2):270-274			
	C23	JENNI, Information Connection: Tips on Treating Acne, http://www.mindconnection.com/library/health/acnecare.htm			
	C24	SCRUGGS et al., The teardrop sign: a rare dermatological reaction to brimonidine, 2004, Br. J. Ophthalmol 84:667			
	C25	RONA'S Skin Remedies, Beauty and Style, http://beauty.ivillage.com/skinbody/facecare/0,,8h9s,00.html			
	C26	PETER LAMA'S Beauty Solutions, Tips for Beautiful Face and Body Skin, Beauty Magazine, http://www.lamasbeauty.com/beauty/solutions/tips_face_skin.htm			
	C27	HEALTH Boards, http://www.healthboards.com/boards/showthread.php?t=5725&highlight=visine+zits			
	C28	BRATSLAVSKY, DERMAdoctor, Skincare articles: your prescription for beautiful skin, http://www.dermadoctor.com/pages/newsletter221.asp			
	C29	ACNE.ORG, http://www.acne.org/messageboard/index.php?showtopic=34267			
	C30	ACNETEAM.COM, http://www.acneteam.com/home-remedies-to-heal-acne-quick.html			
	C31	Tetrahydrozoline hydrochloride, http://www.sigmaaldrich.com/catalog/search/ProductDetail/SIGMA/T4264			
Examiner Signature				Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.